Given the lack of satisfying target therapies for NRAS mutation melanoma and the proven efficacy of immunotherapy for melanoma, immunotherapy is considered as another potential strategy for NRAS/BRAF mutation melanoma. This evidence concerns the gene BRAF and melanoma.